SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

IN THE PRESS
Press Releases
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
June 5, 2025
 · 
11 min read
Press Releases
Immunic to Participate in Investor, Scientific and Industry Conferences in June 2025
June 2, 2025
 · 
6 min read
Press Releases
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
May 29, 2025
 · 
7 min read
Press Releases
Immunic, Inc. Announces Proposed Public Offering
May 29, 2025
 · 
6 min read
Press Releases
Immunic to Participate in Scientific and Industry Conferences in May 2025
May 2, 2025
 · 
6 min read
Press Releases
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
April 30, 2025
 · 
14 min read
Press Releases
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 11, 2025
 · 
6 min read
Press Releases
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
April 1, 2025
 · 
5 min read
Press Releases
Immunic to Participate in Scientific and Investor Conferences in March
March 3, 2025
 · 
6 min read
Press Releases
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
February 27, 2025
 · 
8 min read
Load More
JOBS